Adicet Bio Inc Ordinary Shares ACET
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACET is a good fit for your portfolio.
News
-
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
-
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
-
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
-
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
-
Adicet Bio, Inc. Announces Pricing of Public Offering
Trading Information
- Previous Close Price
- $2.33
- Day Range
- $2.31–2.40
- 52-Week Range
- $1.10–7.50
- Bid/Ask
- $2.32 / $2.35
- Market Cap
- $193.06 Mil
- Volume/Avg
- 534,078 / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 143
- Website
- https://www.adicetbio.com
Comparables
Valuation
Metric
|
ACET
|
ANAB
|
RCUS
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.60 | 6.45 | 2.98 |
Price/Sales | — | 33.55 | 11.52 |
Price/Cash Flow | — | — | — |
Price/Earnings
ACET
ANAB
RCUS
Financial Strength
Metric
|
ACET
|
ANAB
|
RCUS
|
---|---|---|---|
Quick Ratio | 8.28 | 10.62 | 4.35 |
Current Ratio | 8.41 | 10.87 | 4.52 |
Interest Coverage | −6,104.44 | −9.09 | −170.00 |
Quick Ratio
ACET
ANAB
RCUS
Profitability
Metric
|
ACET
|
ANAB
|
RCUS
|
---|---|---|---|
Return on Assets (Normalized) | −38.02% | −23.50% | −20.42% |
Return on Equity (Normalized) | −44.28% | −75.96% | −44.44% |
Return on Invested Capital (Normalized) | −44.36% | −68.56% | −49.53% |
Return on Assets
ACET
ANAB
RCUS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zskmxrqbg | Yfgqc | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ftylwrxt | Yzgjkk | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ddmlndzb | Svbbkp | $105.6 Bil | |
MRNA
| Moderna Inc | Yyfpwxtx | Npgy | $40.8 Bil | |
ARGX
| argenx SE ADR | Xqysbvm | Qvykf | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Wgrzspps | Srm | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qstqqhjm | Tybgw | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jsxlxknh | Cmrdgs | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ssbzjjxrh | Ywkpxbc | $13.6 Bil | |
INCY
| Incyte Corp | Tqlzlhbf | Lnfdm | $12.8 Bil |